reimbursement News
Most Popular reimbursement Story
Study: Sanofi's Multaq shouldn't be a first-line drug
Researchers have dealt another blow to the new Sanofi-Aventis drug Multaq. Approved to treat atrial fibrillation, Multaq proved less effective and no safer than its chief rival, a Cedars-Sinai Heart Read more...
Latest Headlines
- December 15, 2011
- November 22, 2011
- August 9, 2011
- January 20, 2011
- October 28, 2008
- October 14, 2008
- September 11, 2008
- June 19, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
